Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy

Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy

281964

Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy

Rubraca (rucaparib) is superior to chemotherapy at prolonging life without disease worsening in people with advanced ovarian cancer who received at least two prior lines of chemotherapy, according to top-line data from an ongoing Phase 3 trial. Data from the study, called ARIEL4 (NCT02855944), also showed that Rubraca’s safety profile in these women, whose tumors contained mutations in the BRCA DNA repair gene, was consistent with that reported on the therapy’s approved label in Europe and…

You must be logged in to read/download the full post.